Inactive Instrument

Soliton, Inc.

SOLY

US8342511008

Advanced Medical Equipment & Technology

Soliton, Inc. Receives FDA Clearance of Special 510(K)

April 29, 2021 at 01:01 pm

Soliton, Inc., ("Soliton" or the "Company") announced the U.S. Food and Drug Administration ("FDA") clearance of the Company's special 510(k) for modifications to its RESONIC™ device.

Latest news about Soliton, Inc.

Soliton, Inc.(NasdaqCM:SOLY) dropped from S&P TMI Index	20/12/21	CI
Soliton, Inc.(NasdaqCM:SOLY) dropped from NASDAQ Composite Index	16/12/21	CI
Allergan plc completed the acquisition of Soliton, Inc. for approximately $570 million.	15/12/21	CI
Soliton Up 12% as Nasdaq Alert Says Sale to AbbVie Is Scheduled to Close Thursday	14/12/21	DJ
Soliton, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	12/11/21	CI
Soliton, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021	12/08/21	CI
Soliton : AbbVie, Soliton Providing FTC Extra Time to Review Proposed Deal	02/07/21	MT
SOLITON : Roth Capital Downgrades Soliton to Neutral From Buy	02/06/21	MT
Soliton, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	13/05/21	CI
SOLITON : Cantor Fitzgerald Downgrades Soliton to Neutral from Overweight, Adjusts Price Target to $22.60 from $25	13/05/21	MT
SOLITON : Maxim Group Downgrades Soliton to Hold From Buy	11/05/21	MT
Sector Update: Health Care Stocks Hanging On For Modest Rise	10/05/21	MT
Sector Update: Health Care Stocks Extending Monday Gains, Overcoming Biotech Weakness	10/05/21	MT
Sector Update: Health Care	10/05/21	MT
AbbVie's Allergan Aesthetics to Buy Soliton	10/05/21	DJ
AbbVie : Allergan Aesthetics to Acquire Soliton for $22.60 per Share	10/05/21	MT
Allergan plc entered into a definitive agreement to acquire Soliton, Inc. for approximately $510 million.	09/05/21	CI
Soliton, Inc. Announces Introducing RESONIC™	05/05/21	CI
Soliton, Inc. Receives FDA Clearance of Special 510(K)	29/04/21	CI
Soliton : 501k Application for RESONIC Device Accepted by FDA	15/04/21	MT
Soliton, Inc. Provides Special 510(K) and Commercialization Update	15/04/21	CI
Soliton : Initiates Second Animal Study for Potential Liver Fibrosis Treatment	09/03/21	MT
Soliton Announces Initiation of Second Animal Study for Potential RAP Treatment of Liver Fibrosis	09/03/21	CI
Soliton, Inc. Reports Earnings Results for the Fourth Quarter and Year Ended December 31, 2020	04/03/21	CI
Soliton Selects RESONIC™ As Brand Name for FDA-Cleared Rapid Acoustic Pulse Device	02/03/21	CI

Soliton Inc is a medical technology company. The Company is focused on developing and commercializing products utilizing its designed acoustic shockwave technology platform referred to as Rapid Acoustic Pulse (RAP). It develops products for the removal of tattoos and the reduction of cellulite. The RAP device in coordination with the pulsed laser removes ink pigment from the macrophages. Its RAP device uses pulses of designed acoustic shockwaves to disrupt cellular structures in the dermal and subdermal tissue. It's designed shockwave allows it to target the stiffness between cellular structures and generate an effect that represents a platform technology in tattoo removal, cellulite treatment, fibrotic scar treatment and other indications. Its technology allows the disruption of targeted structures within the skin with minimal discomfort and without additional treatment-related downtime for tattoo removal or any downtime for cellulite treatment.

Sector

Advanced Medical Equipment & Technology

More about the company